Gene therapy: evidence, value and affordability in the US health care system Read more about Gene therapy: evidence, value and affordability in the US health care system
Gene therapy of hemoglobinopathies: progress and future challenges Read more about Gene therapy of hemoglobinopathies: progress and future challenges
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease Read more about The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease
Addressing the value of gene therapy and enhancing patient access to transformative treatments Read more about Addressing the value of gene therapy and enhancing patient access to transformative treatments
Value-based pricing for emerging gene therapies: The economic case for a higher cost-effectiveness threshold Read more about Value-based pricing for emerging gene therapies: The economic case for a higher cost-effectiveness threshold
Gene therapies: The challenge of super-high-cost treatments and how to pay for them Read more about Gene therapies: The challenge of super-high-cost treatments and how to pay for them
CRISPR democracy: Gene editing and the need for inclusive deliberation Read more about CRISPR democracy: Gene editing and the need for inclusive deliberation
New treatments for serious conditions: ethical implications Read more about New treatments for serious conditions: ethical implications
Issues and ethical considerations in pharmaco-oncogenomics Read more about Issues and ethical considerations in pharmaco-oncogenomics
